BTG (LON:BTG)‘s stock had its “hold” rating restated by investment analysts at Peel Hunt in a research note issued to investors on Tuesday, November 14th. They presently have a GBX 680 ($9.11) price objective on the stock. Peel Hunt’s price objective would indicate a potential downside of 5.69% from the stock’s current price.
Several other research firms have also recently commented on BTG. Numis Securities reissued a “buy” rating and set a GBX 900 ($12.05) target price on shares of BTG in a research note on Wednesday, August 9th. Stifel Nicolaus reissued a “buy” rating and set a GBX 800 ($10.71) target price on shares of BTG in a research note on Wednesday, August 30th. J P Morgan Chase & Co restated a “neutral” rating on shares of BTG in a research report on Monday, September 18th. Finally, Deutsche Bank restated a “buy” rating and set a GBX 775 ($10.38) price objective on shares of BTG in a research report on Thursday, September 21st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of GBX 771.63 ($10.33).
Shares of BTG (BTG) traded down GBX 3.95 ($0.05) during mid-day trading on Tuesday, hitting GBX 721.05 ($9.66). 396,563 shares of the stock traded hands, compared to its average volume of 747,686. BTG has a fifty-two week low of GBX 528.36 ($7.08) and a fifty-two week high of GBX 779 ($10.43).
COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/btg-plc-btg-stock-rating-reaffirmed-by-peel-hunt-2/1782344.html.
BTG Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with our FREE daily email newsletter.